Editorial: Analyzing Treatment and Prescribing in Large Administrative Datasets With a Lens on Equity

J Am Acad Child Adolesc Psychiatry. 2021 Jul;60(7):818-820. doi: 10.1016/j.jaac.2020.12.026. Epub 2021 Mar 6.

Abstract

In this issue of the Journal, Bushnell and colleagues1 present findings from their analysis of a commercial insurance administrative dataset, examining the ways that antipsychotics are used in young children (aged 2-7 years) in the United States. From 2009 to 2017, they find that the use of antipsychotics decreased and there was a shift toward use of medications in alignment with evidence-based standards. The most common conditions for use of antipsychotics included pervasive developmental disorders, externalizing disorders, and attention-deficit/hyperactivity disorder. More troubling were the findings that less than half of young children on antipsychotics had a visit with a psychiatrist, and only a third of children had evidence of a minimum dose of psychotherapy. These findings deserve attention and should be a cause for strengthening the use of existing treatment guidelines for preschool and younger children. They should also prompt enhanced advocacy to expand access to evidence-based mental health care for children that includes high-quality psychiatric assessment, treatment, and psychotherapy. The latter includes increasing the number of child and adolescent psychiatrists who focus on preschool-aged and younger children.

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Adolescent
  • Antipsychotic Agents* / adverse effects
  • Attention Deficit Disorder with Hyperactivity* / drug therapy
  • Child
  • Child Development Disorders, Pervasive*
  • Child, Preschool
  • Humans
  • Psychiatry*
  • Psychotherapy
  • United States

Substances

  • Antipsychotic Agents